Literature DB >> 25894399

Clinicopathological Meaning of Size of Main-Duct Dilatation in Intraductal Papillary Mucinous Neoplasm of Pancreas: Proposal of a Simplified Morphological Classification Based on the Investigation on the Size of Main Pancreatic Duct.

Mee Joo Kang1, Jin-Young Jang, Selyeong Lee, Taesung Park, Seung Yeoun Lee, Sun-Whe Kim.   

Abstract

BACKGROUND: The 2012 consensus guideline on intraductal papillary mucinous neoplasm of the pancreas (IPMN) described a three-stage criteria involving main pancreatic duct (MPD) size with definitions of malignancy relevant for treatment decisions. Re-evaluation and simplification of this classification for clinicians are warranted.
METHODS: Data from the Seoul National University Hospital of 375 consecutive patients with pathology-confirmed IPMN after surgery were analyzed. The association between clinicopathologic characteristics of IPMN and MPD size was assessed. The cut-off value of MPD size for a current definition of malignancy prediction was calculated.
RESULTS: Diagnostic accuracy for malignancy was highest when the cut-off value of MPD size was 7 mm (area under the curve=0.7126). Dichotomizing IPMN into MPD≤7 mm versus MPD> mm, patient age (p=0.039), sex (p=0.001), presence of mural nodule (p<0.001), and invasiveness risk (13.2 vs. 39.8%, p<0.001) resulted in significantly different results. Mural nodule-negative patients with MPD>7 mm had a significantly lower 5-year survival rate than those with MPD≤7 mm (78.4 vs. 91.4%, p=0.006). Among patients with MPD size≤7 mm, elevated serum CA 19-9 and mural nodule were independent risk factors of malignancy. Patients with MPD size≤7 mm without these risk factors had malignancy risk of 2.6%.
CONCLUSION: Using the definition of malignancy provided in the 2012 guideline, the MPD size> mm criterion was statistically driven. The current morphologic classification of IPMN can be simplified as branch-duct-predominant IPMN (MPD≤7 mm)' and main-duct-predominant IPMN (MPD> mm). Patients who are determined to have main-duct-predominant IPMN and branch-duct-predominant IPMN with elevated serum CA 19-9 or mural nodule are recommended to undergo surgical treatment.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25894399     DOI: 10.1007/s00268-015-3062-0

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  32 in total

Review 1.  International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas.

Authors:  Masao Tanaka; Suresh Chari; Volkan Adsay; Carlos Fernandez-del Castillo; Massimo Falconi; Michio Shimizu; Koji Yamaguchi; Kenji Yamao; Seiki Matsuno
Journal:  Pancreatology       Date:  2006       Impact factor: 3.996

2.  Intraductal papillary mucinous neoplasm of pancreas: multi-detector row CT with 2D curved reformations--correlation with MRCP.

Authors:  Dushyant V Sahani; Rajagopal Kadavigere; Michael Blake; Carlos Fernandez-Del Castillo; Gregory Y Lauwers; Peter F Hahn
Journal:  Radiology       Date:  2006-02       Impact factor: 11.105

3.  Management of intraductal papillary-mucinous neoplasm of the pancreas: treatment strategy based on morphologic classification.

Authors:  Masahiro Serikawa; Tamito Sasaki; Yoshifumi Fujimoto; Kenichi Kuwahara; Kazuaki Chayama
Journal:  J Clin Gastroenterol       Date:  2006-10       Impact factor: 3.062

Review 4.  Cyst features and risk of malignancy in intraductal papillary mucinous neoplasms of the pancreas: a meta-analysis.

Authors:  Neeraj Anand; Kartik Sampath; Bechien U Wu
Journal:  Clin Gastroenterol Hepatol       Date:  2013-02-13       Impact factor: 11.382

5.  MR cholangiopancreatographic differentiation of benign and malignant intraductal mucin-producing tumors of the pancreas.

Authors:  H Irie; H Honda; H Aibe; T Kuroiwa; K Yoshimitsu; K Shinozaki; K Yamaguchi; M Shimada; K Masuda
Journal:  AJR Am J Roentgenol       Date:  2000-05       Impact factor: 3.959

6.  Cyst growth rate predicts malignancy in patients with branch duct intraductal papillary mucinous neoplasms.

Authors:  Mee Joo Kang; Jin-Young Jang; Soo Jin Kim; Kyoung Bun Lee; Ji Kon Ryu; Yong-Tae Kim; Yong Bum Yoon; Sun-Whe Kim
Journal:  Clin Gastroenterol Hepatol       Date:  2010-09-17       Impact factor: 11.382

7.  Predictive factors for malignancy in intraductal papillary-mucinous tumours of the pancreas.

Authors:  M Sugiyama; Y Izumisato; N Abe; T Masaki; T Mori; Y Atomi
Journal:  Br J Surg       Date:  2003-10       Impact factor: 6.939

8.  Abdominal lymphadenopathy: spectrum of CT findings.

Authors:  D M Einstein; A A Singer; W A Chilcote; R K Desai
Journal:  Radiographics       Date:  1991-05       Impact factor: 5.333

9.  Is it necessary to follow patients after resection of a benign pancreatic intraductal papillary mucinous neoplasm?

Authors:  Jin He; John L Cameron; Nita Ahuja; Martin A Makary; Kenzo Hirose; Michael A Choti; Richard D Schulick; Ralph H Hruban; Timothy M Pawlik; Christopher L Wolfgang
Journal:  J Am Coll Surg       Date:  2013-02-06       Impact factor: 6.113

10.  Predictors of malignancy in intraductal papillary mucinous neoplasm of the pancreas: analysis of 310 pancreatic resection patients at multiple high-volume centers.

Authors:  Yasuhiro Shimizu; Hiroki Yamaue; Hiroyuki Maguchi; Kenji Yamao; Seiko Hirono; Manabu Osanai; Susumu Hijioka; Waki Hosoda; Yasushi Nakamura; Toshiya Shinohara; Akio Yanagisawa
Journal:  Pancreas       Date:  2013-07       Impact factor: 3.327

View more
  5 in total

1.  Evaluation of the International Consensus Guidelines for the Surgical Resection of Intraductal Papillary Mucinous Neoplasms.

Authors:  Mariko Tsukagoshi; Kenichiro Araki; Fumiyoshi Saito; Norio Kubo; Akira Watanabe; Takamichi Igarashi; Norihiro Ishii; Takahiro Yamanaka; Ken Shirabe; Hiroyuki Kuwano
Journal:  Dig Dis Sci       Date:  2017-06-30       Impact factor: 3.199

Review 2.  [Resection of main duct and mixed type IPMN ≥5 mm].

Authors:  G O Ceyhan; F Scheufele; H Friess
Journal:  Chirurg       Date:  2017-11       Impact factor: 0.955

Review 3.  Ductal Dilatation of ≥5 mm in Intraductal Papillary Mucinous Neoplasm Should Trigger the Consideration for Pancreatectomy: A Meta-Analysis and Systematic Review of Resected Cases.

Authors:  Y H Andrew Wu; Atsushi Oba; Laurel Beaty; Kathryn L Colborn; Salvador Rodriguez Franco; Ben Harnke; Cheryl Meguid; Daniel Negrini; Roberto Valente; Steven Ahrendt; Richard D Schulick; Marco Del Chiaro
Journal:  Cancers (Basel)       Date:  2021-04-22       Impact factor: 6.639

4.  European evidence-based guidelines on pancreatic cystic neoplasms.

Authors: 
Journal:  Gut       Date:  2018-03-24       Impact factor: 23.059

Review 5.  Predictive performance of factors associated with malignancy in intraductal papillary mucinous neoplasia of the pancreas.

Authors:  M Heckler; L Brieger; U Heger; T Pausch; C Tjaden; J Kaiser; M Tanaka; T Hackert; C W Michalski
Journal:  BJS Open       Date:  2018-02-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.